Evaluating the Difference Between COVID-19-Associated Telogen Effluvium and Telogen Effluvium Due to Other Causes

Evaluating the Difference Between COVID-19-Associated Telogen Effluvium and Telogen Effluvium Due to Other Causes

Authors

  • Didem Kazan Kutahya Health Science University, Evliya Celebi Training and Research Hospital, Dermatology and Venerology Clinic,Kutahya, Turkey
  • Defne Ozkoca Zonguldak Atatürk State Hospital, Dermatology and Venerology Clinic, Zonguldak, Turkey
  • Nazlı Dizen Namdar Kutahya Health Science University, Evliya Celebi Training and Research Hospital, Dermatology and Venerology Clinic,Kutahya, Turkey

Keywords:

telogen efflivium, dermoscopy, trichoscopy, SARS-CoV-2

Abstract

Introduction: Telogen effluvium (TE) is a common type of non-cicatricial alopecia, and it is reported frequently in patients with SARS-CoV-2 infection.

Objectives: Herein, we aimed to examine the demographic, dermoscopic, and laboratory features of the patients with SARS-CoV-2 associated TE (CATE) and compare them with TE due to other causes (TEDOC) according to these features.

Methods: In this retrospective case-control study we evaluated the patients who were diagnosed with TE and were above 18 years of age between April and June 2022. The patients were divided into two groups based on their medical history and SARS-CoV-2 PCR positivity. The first group included patients with CATE and positive SARS-CoV-2 PCR test results in the last 3 months. The second group consisted of patients with TEDOC. Patients' gender, age, disease duration, additional systemic disease, dermoscopic findings, and laboratory results were recorded.

Results: A total of 92 patients, 86 (93.5%) female, and 6 (6.5%) male, were included in the study. CATE was detected in 52 (56.5%) patients whereas 40 (44.5%) patients had TEDOC. The mean time between the onset of SARS-CoV-2 infection and hair loss complaint was calculated as 64.8 + 25.6 days, and this time was significantly shorter than patients with TEDOC (p=0.003). The dermoscopic evaluation showed that empty follicular openings and yellow dots were statistically higher in patients with CATE, whereas short regrowing hair were markedly higher in patients with TEDOC. (p=0.001, p=0.001, and p=0.001, respectively)

Conclusions: CATE is characterized by excessive hair-shedding that begins sooner after infection than classic TE. Dermoscopic findings can assist clinicians in diagnosis.

References

Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol. 1993;129(3):356-363. doi: 10.1001/archderm.129.3.356. PMID: 8447677.

Turkmen D, Altunisik N, Sener S, et al. Evaluation of the effects of COVID-19 pandemic on hair diseases through a web-based questionnaire. Dermatol Ther. 2020;33:e13923. doi: 10.1111/dth.13923. Epub 2020 Jul 16. PMID: 32594627; PMCID: PMC7361059.

Aryanian Z, Balighi K, Hatami P, Afshar ZM, Mohandesi NA. The role of SARS-CoV-2 infection and its vaccines in various types of hair loss. Dermatol Ther. 2022;35(6):e15433. doi: 10.1111/dth.15433. Epub 2022 Apr 1. PMID: 35266262; PMCID: PMC9111640.

Hernández Arroyo J, Izquierdo-Condoy JS, Ortiz-Prado E. A Case Series and Literature Review of Telogen Effluvium and Alopecia Universalis after the Administration of a Heterologous COVID-19 Vaccine Scheme. Vaccines (Basel). 2023;11(2):444. doi: 10.3390/vaccines11020444. PMID: 36851320; PMCID: PMC9968192.

Guarnieri G, Bertagna De Marchi L, Marcon A, Panunzi S, Batani V, Caminati M, Furci F, Senna G, Alaibac M, Vianello A. Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia. Ann Med. 2022;54(1):869-874. doi: 10.1080/07853890.2022.2054026. PMID: 35341398; PMCID: PMC8959503.

Olds H, Liu J, Luk K, Lim HW, Ozog D, Rambhatla PV. Telogen effluvium associated with COVID-19 infection. Dermatol Ther. 2021;34(2):e14761. doi: 10.1111/dth.14761. Epub 2021 Jan 14. PMID: 33405302; PMCID: PMC7883200.

Starace M, Iorizzo M, Sechi A, et al. Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management. JAAD Int. 2021;5:11-18. doi: 10.1016/j.jdin.2021.07.006. Epub 2021 Aug 3. PMID: 34368790; PMCID: PMC8328568.

Babaei K, Kavoussi H, Rezaei M, Kavoussi R. Characteristics of telogen efflivium in COVID-19 in western Iran (2020). An Bras Dermatol. 2021 Nov-Dec;96(6):688-692. doi: 10.1016/j.abd.2021.05.006. Epub 2021 Sep 15. PMID: 34593265; PMCID: PMC8440166.

Moreno-Arrones OM, Lobato-Berezo A, Gomez-Zubiaur A, et al. SARS-CoV-2-induced telogen effluvium: a multicentric study. J Eur Acad Dermatol Venereol. 2021;35(3):e181-e183. doi: 10.1111/jdv.17045. Epub 2020 Dec 9. PMID: 33220124; PMCID: PMC7753386.

Xiong Y, Harmon CS. Interleukin-1beta is differentially expressed by human dermal papilla cells in response to PKC activation and is a potent inhibitor of human hair follicle growth in organ culture. J Interferon Cytokine Res. 1997;17(3):151-157. doi: 10.1089/jir.1997.17.151. PMID: 9085940.

Mandt N, Geilen CC, Wrobel A, et al. Interleukin-4 induces apoptosis in cultured human follicular keratinocytes, but not in dermal papilla cells. Eur J Dermatol. 2002;12(5):432-438. PMID: 12370129.

Rosei CA, Gaggero A, Famà F, Malerba P, Chiarini G, Nardin M, et al. Skin capillary alterations in patients with acute SarsCoV2 infection. J Hypertens. 2022;40(12):2385–93. doi: 10.1097/HJH.0000000000003271. Epub 2022 Aug 18. PMID: 35983856; PMCID: PMC9640263.

Michelini S, Caro G, Di Fraia M, Fortuna M, Magri F, Gomes VV, et al. Telogen effluvium in SARS-CoV-2 infection: histological aspects. J Eur Acad Dermatol Venereol. 2023; 8:1– 3. doi: 10.1111/jdv.19015. Epub ahead of print. PMID: 36883793.

Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46-e47. doi: 10.1016/S2213-2600(20)30216-2. Epub 2020 Apr 27. PMID: 32353251; PMCID: PMC7185942.

Rossi A, Magri F, Sernicola A, Michelini S, Caro G, Muscianese M, et al. Telogen effluvium after SARS-CoV-2 infection: a series of cases and possible Pathogenetic mechanisms. Skin Appendage Disord. 2021;21(5):1–5. doi: 10.1159/000517223. PMID: 34373830; PMCID: PMC8339054.

Rizzetto G, Diotallevi F, Campanati A, et al. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2021;34(1):e14547. doi: 10.1111/dth.14547. Epub 2020 Nov 23. PMID: 33190397; PMCID: PMC7744849.

Kinoshita-Ise M, Sachdeva M. Update on trichoscopy: Integration of the terminology by systematic approach and a proposal of a diagnostic flowchart. J Dermatol. 2022;49(1):4-18. doi: 10.1111/1346-8138.16233. Epub 2021 Nov 22. PMID: 34806223.

Hussain N, Agarwala P, Iqbal K, et al. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation. J Med Virol. 2022;94(4):1391-1401. doi: 10.1002/jmv.27534. Epub 2021 Dec 28. PMID: 34931698.

Lv S, Wang L, Zou X, et al. A Case of Acute Telogen Effluvium After SARS-CoV-2 Infection. Clin Cosmet Investig Dermatol. 2021;14:385-387. doi: 10.2147/CCID.S307982. PMID: 33889006; PMCID: PMC8057787.

Saber M, Mardani E, Shahmoradi Z. Scalp capillarectasia as a trichoscopic sign of COVID-19-associated telogen effluvium. J Cosmet Dermatol. 2023;00:1–2. doi: 10.1111/jocd.15717. Epub 2023 Mar 9. PMID: 36896459.

Inamadar AC. Covid Induced Telogen Effluvium (CITE): An Insight. Indian Dermatol Online J. 2022 Jun 24;13(4):445-448. doi: 10.4103/idoj.idoj_139_22. PMID: 36262583; PMCID: PMC9574152.

Grymowicz M, Rudnicka E, Podfigurna A, et al. Hormonal effects on hair follicles. Int J Mol Sci. 2020;21(15):5342. doi: 10.3390/ijms21155342. PMID: 32731328; PMCID: PMC7432488.

Aksoy H, Yıldırım UM, Ergen P, Gürel MS. COVID-19 induced telogen effluvium. Dermatol Ther. 2021;34(6):e15175. doi: 10.1111/dth.15175. Epub 2021 Nov 6. PMID: 34708909; PMCID: PMC8646871.

Downloads

Published

2024-07-31

How to Cite

1.
Evaluating the Difference Between COVID-19-Associated Telogen Effluvium and Telogen Effluvium Due to Other Causes . Dermatol Pract Concept [Internet]. 2024 Jul. 31 [cited 2024 Dec. 5];14(3):e2024170. Available from: https://www.dpcj.org/index.php/dpc/article/view/4095

Share